Αρχική World News Patients with Breast, Colorectal, and Pancreatic Cancers With ATM, CHEK2, or PALB2... World News Patients with Breast, Colorectal, and Pancreatic Cancers With ATM, CHEK2, or PALB2 PVs Have Similar Mortality to the Average Genetically Tested Patients Από Ogkologos - 18 Μαρτίου, 2025 914 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a population-based study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR What to Know About Peer-Reviewed Cancer Information and Its Role in... 10 Αυγούστου, 2022 Neoadjuvant Nivolumab Plus Ipilimumab Shows Trend Towards Long-Term Clinical Benefit versus... 24 Φεβρουαρίου, 2025 Vaping Pods Produce High Nicotine Levels in Young Users 5 Οκτωβρίου, 2018 FDA Expands Indications for Lutetium Lu 177 Vipivotide Tetraxetan to Include... 25 Απριλίου, 2025 Φόρτωση περισσοτέρων HOT NEWS The Galleri multi-cancer blood test: what you need to know 关于肺癌生物标志物检测应当了解的信息:专家问答 Lockdown Keeping Young Mother with Metastatic Breast Cancer from Saying Goodbye... Duration of Bevacizumab Maintenance of 15 Months Remains the Standard in...